Last week at the 23andMe headquarters, over 100 researchers gathered together for the company’s annual Genome Research Day.
Our ability to reconstruct physical features from DNA is advancing, but can we ensure the privacy of “anonymised” genetic data if we can predict the face of its owner?
The U.K. Prime Minister, Theresa May has made her first appearance in a series on industrial strategy, whereby she has pledged millions of pounds of government funding to develop artificial intelligence to transform outcomes through early diagnosis of cancer and chronic disease.
Scientists have located sections of DNA that appear to play a role in controlling whether an individual’s skin burns or tans, which has laid the groundwork for genetic tests that could predict people’s responses to sunlight.
Researchers have learned that artificial intelligence resembles the working of a human brain, opening up new possibilities to test how the brain works.
Most people don’t like going to the doctor. That’s why Theodoros Zanos, a researcher at The Feinstein Institute for Medical Research, is working on a technology that might one day be able to listen to, and decode the body’s electrical signals, catching warning signs of illness.
Color Genomics unveils its plan to give people a peek into their genetic risk, by offering a test for hereditary cancer and high cholesterol. But, they are offering more than just that.
Much of medicine is about information — the data that helps doctors make the right choices about our treatment. So how will the revolution in big data impact complex healthcare systems like the NHS?
Geisinger Health System CEO, Dr. David Feinberg reveals health system’s pioneering precision health efforts will be recommended to every patient.
A new cell-based medicine is offering hope for children suffering from incurable nerve tissue cancer, posing a dilemma for investors.
A new app helps patients with muscular dystrophy control a robotic exoskeleton that assists with everyday tasks like drinking a glass of water or turning on a light switch.
U.S. regulators approved Novartis’ cell therapy Kymriah for the treatment of patients with a second type of blood cancer.